Browse EX-10 agreements

September 8, 2026

Matthew Leoni

[***]

[***]

Email: [***]

Re: Offer of Employment

Dear Matthew:

On behalf of Korsana Biosciences, Inc. (f/k/a Cyclerion Therapeutics, Inc., the “Company”), I am very pleased to offer you continued employment as Chief Medical Officer (the “Role”) pursuant to this letter agreement (the “Agreement”). This Agreement will amend and restate the June 5, 2026 letter agreement between you and Korsana Biosciences Operating Company, LLC (f/k/a Korsana Biosciences, Inc., “OpCo”), provided you accept such offer as indicated by your signature below, effective as of the consummation of the Company’s acquisition of OpCo (the “Effective Date”). You will be employed by OpCo, a subsidiary of the Company, and references to the Company with respect to your employing entity shall include OpCo.

…

**KORSANA BIOSCIENCES, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

1.	**Purpose **

The purpose of this Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated Contributions. The Company’s intention is to have the Plan qualify as an “employee stock purchase plan” under Section 423 of the Code. The provisions of the Plan, accordingly, will be construed to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code.

2.	**Definitions. **

As used in the Plan, the following terms shall have the meanings set forth below:

(a) “Administrator” means the Compensation Committee of the Board (or any successor committee), or such other committee as designated by the Board to administer the Plan under Section*** 14*.

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

**CONTINGENT VALUE RIGHTS AGREEMENT **

This **CONTINGENT VALUE RIGHTS AGREEMENT **(this “Agreement”), dated as of September 8, 2026, is entered into by and between Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as the “Rights Agent” (as defined herein).

**RECITALS **

…

**KORSANA BIOSCIENCES, INC. **

**2026 STOCK INCENTIVE PLAN **

1.	**Purpose **

The purpose of this Korsana Biosciences, Inc. 2026 Stock Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Korsana Biosciences, Inc. and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the best available employees, officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate Participants to optimize the profitability and growth of the Company through incentives that are consistent with the Company’s goals and that link the personal interests of Participants to those of the Company’s stockholders. The Plan provides for the grant of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Other Stock-Based Awards and for Incentive Bonu

…

**INDEMNIFICATION AGREEMENT **

This Indemnification Agreement (this “Agreement”) is entered into on __________ by and between Korsana Biosciences, Inc., a Massachusetts corporation (the “Company”), and __________ (the “Indemnitee”). Notwithstanding the date of execution of this Agreement, each of the parties hereto agrees that their respective rights, duties and obligations pursuant to this Agreement shall come into effect upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.

**RECITALS **

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that the inability to attract and retain qualified persons as directors and officers is detrimental to the best interests of the Company and that the Company should act to assure such persons that there shall be adequate certainty of protection through insurance and indemnification against risks of claims and actions against them arising out of their service to and activities on behalf of the Company;

…

September 8, 2026

Jonathan Violin

[***]

[***]

Email: [***]

Re: Offer of Employment

Dear Jon:

On behalf of the Board of Directors (the “Board”) of Korsana Biosciences, Inc. (f/k/a Cyclerion Therapeutics, Inc., the “Company”), I am very pleased to offer you continued employment as Chief Executive Officer (the “Role”) and a member of the Board pursuant to this letter agreement (the “Agreement”). This Agreement will amend and restate the December 24, 2025 letter agreement between you and Korsana Biosciences Operating Company, LLC (f/k/a Korsana Biosciences, Inc., “OpCo”), provided you accept such offer as indicated by your signature below, effective as of the consummation of the Company’s acquisition of OpCo (the “Effective Date”). You will be employed by OpCo, a subsidiary of the Company, and references to the Company with respect to your employing entity shall include OpCo.

…

Exhibit10.1

ARTIVABIOTHERAPEUTICS, INC.

2024 EQUITYINCENTIVEPLAN

ADOPTEDBYTHEBOARDOFDIRECTORS: JULY11, 2024

APPROVEDBYTHESTOCKHOLDERS: JULY11, 2024

AMENDEDBYTHEBOARDOFDIRECTORS: APRIL17, 2025

APPROVEDBYTHESTOCKHOLDERS: June 24,2025

AMENDEDBYTHEBOARDOFDIRECTORS: July15, 2026

APPROVEDBYTHESTOCKHOLDERS: September8, 2026

1.	GENERAL.

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

***SEPARATION AGREEMENT AND GENERAL RELEASE ***

UniFirst Corporation (the “Company”) and Kelly Rooney (the “Executive”) hereby agree that this Separation Agreement and General Release (the “Agreement”) sets forth their complete agreement and understanding regarding the separation of Executive’s employment with the Company.

1. Separation Date. Executive’s employment with the Company will end effective September 11, 2026 (the “Separation Date”). As of the Separation Date, Executive will have resigned from all of Executive’s positions (as a director, manager, officer, employee or otherwise) at the Company. The Separation Date will be the termination date of Executive’s employment for purposes of active participation in and coverage under all employee benefit plans sponsored by or through the Company. On the Separation Date, the Company will provide Executive with a final paycheck that includes Executive’s earned wages through the Separation Date and accrued and unused vacation (if any), less applicable taxes and withholdings, and any business expense reimbursements reported by

…

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN QUALIFIED FOR DISTRIBUTION BY PROSPECTUS IN CANADA AND MAY NOT BE OFFERED OR SOLD IN CANADA DURING THE COURSE OF THEIR DISTRIBUTION EXCEPT PURSUANT TO A CANADIAN PROSPECTUS OR AN AVAILABLE EXEMPTION FROM THE APPLICABLE PROSPECTUS REQUIREMENTS.

…

** **

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 11, 2026, between Sphere 3D Corp., a corporation incorporated under the laws of Ontario (the “Company”), and each of the purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of September 8, 2026, between the Company and each Purchaser (the “Purchase Agreement”).

The Company and each Purchaser hereby agrees as follows:

1. Definitions.

Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the respective meanings given to such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Advice” shall have the meaning set forth in Section ‎6(b).

…

** **

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of September 8, 2026, between Sphere 3D Corp., a corporation incorporated under the laws of Ontario (the “Company”), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, if applicable, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

Article I
DEFINITIONS

** **

…

**Execution Version **

**AMENDMENT NO. 1 **

AMENDMENT NO. 1, dated as of September 9, 2026 (this “Amendment”), to the Loan Agreement dated as of February 21, 2025 (as amended, supplemented, amended and restated or otherwise modified from time to time prior to the date hereof, the “Loan Agreement”) among SANDISK CORPORATION, a Delaware corporation (the “Lead Borrower”), the additional borrowers from time to time party thereto, each lender from time to time party thereto (collectively, the “Lenders” and individually, a “Lender”), JPMORGAN CHASE BANK, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) and the other parties thereto. Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.

…